Article Information
History
- October 12, 2021.
Article Versions
- You are currently viewing Version 1 of this article (October 12, 2021 - 00:49).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Gregory M. Miller1,
- J. Austin Ellis4,
- Rangaprasad Sarangarajan1,
- Amay Parikh2,
- Leonardo O. Rodrigues1,
- Can Bruce1,
- Nischal Mahaveer Chand1,
- Steven R. Smith2,
- Kris Richardson1,
- Raymond Vazquez3,
- Michael A. Kiebish1,
- Chandran Haneesh2,
- Elder Granger1,
- Judy Holtz2,
- Jacob Hinkle5,
- Niven R. Narain1,
- Bret Goodpaster2,
- Jeremy C. Smith6,7 and
- Daniel S. Lupu2,*
- 1BERG, Framingham, MA 01701
- 2Translational Research Institute, AdventHealth Research Institute, Orlando, FL 32804, USA
- 3AdventHealth Information Technology, Orlando, FL 32804
- 4National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
- 5Computational Sciences and Engineering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
- 6Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN 37996, USA
- 7UT/ORNL Center for Molecular Biophysics, Oak Ridge National Laboratory, Oak Ridge, TN 37830, USA
- ↵*Corresponding Author:
Daniel Lupu, MD, PhD, Translational Research Institute, AdventHealth Research Institute, 301 E Princeton St, Orlando, FL 32804; Email: Daniel.Lupu{at}adventhealth.com; Phone: 407 303 2076
Posted October 12, 2021.
Ondansetron use is associated with lower COVID-19 mortality in a Real-World Data network-based analysis
